Teva, Sandoz, Mylan, Pfizer…Who Sees Value In The US Biosimilars Market?

 
• By Dean Rudge
  
Doors
Biosimilar players are trying to kick down doors in the multi-billion dollar US biologics space • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products